Beam Therapeutics/$BEAM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Ticker
$BEAM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
393
ISIN
US07373V1052
Website
BEAM Metrics
BasicAdvanced
$2B
-
-$4.62
2.35
-
Price and volume
Market cap
$2B
Beta
2.35
52-week high
$35.25
52-week low
$13.53
Average daily volume
2.2M
Financial strength
Current ratio
8.814
Quick ratio
8.619
Long term debt to equity
12.903
Total debt to equity
14.079
Profitability
EBITDA (TTM)
-408.7
Gross margin (TTM)
-475.12%
Net profit margin (TTM)
-609.24%
Operating margin (TTM)
-677.47%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-19.05%
Return on equity (TTM)
-38.04%
Valuation
Price to revenue (TTM)
26.981
Price to book
1.78
Price to tangible book (TTM)
1.78
Price to free cash flow (TTM)
-4.752
Free cash flow yield (TTM)
-21.04%
Free cash flow per share (TTM)
-430.31%
Growth
Revenue change (TTM)
-82.38%
Earnings per share change (TTM)
172.32%
3-year revenue growth (CAGR)
1.80%
3-year earnings per share growth (CAGR)
8.76%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
Bulls say / Bears say
Beam Therapeutics reported positive initial data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency, showing durable, dose-dependent increases in total and functional AAT, and reductions in mutant Z-AAT levels. (investing.com)
The company's BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease demonstrated that all treated patients achieved Hemoglobin F induction of over 60% and Hemoglobin S reduction to below 40%, with no vaso-occlusive crises post-treatment. (gurufocus.com)
Beam Therapeutics received Orphan Drug Designation from the U.S. FDA for both BEAM-101 and BEAM-302, potentially facilitating expedited development and regulatory processes. (globenewswire.com)
In Q1 2025, Beam Therapeutics reported a net loss of over $109 million, deepening from the previous year's loss, and missed analyst revenue expectations, leading to a significant stock price decline. (nasdaq.com)
The company faces high competition in the sickle cell disease and Alpha-1 Antitrypsin Deficiency sectors, with analysts expressing concerns about its ability to differentiate its therapies in a crowded market. (investing.com)
Insider selling activity, including significant share sales by the CEO and President, may raise concerns about internal confidence in the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
BEAM News
AllArticlesVideos
Top Stock Pick Report: V-Shaped Rallies Everywhere
Schaeffers Research·3 weeks ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
GlobeNewsWire·1 month ago
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beam Therapeutics stock?
Beam Therapeutics (BEAM) has a market cap of $2B as of July 18, 2025.
What is the P/E ratio for Beam Therapeutics stock?
The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of July 18, 2025.
Does Beam Therapeutics stock pay dividends?
No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Beam Therapeutics dividend payment date?
Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.
What is the beta indicator for Beam Therapeutics?
Beam Therapeutics (BEAM) has a beta rating of 2.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.